Amines

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Lundi, août 2, 2021
Life sciences, Drugs, Health sciences, Amines, Antipruritics, Difelikefalin, Piperidines, Biopharmaceutical, Investigational New Drug

ET to report second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET to report second quarter 2021 financial results and provide a corporate update.
  • To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1568596.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs.
  • CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

Small Pharma Reports First Fiscal Quarter 2021 Highlights

Retrieved on: 
Vendredi, juillet 30, 2021
Amines, Psychoactive drugs, Ayahuasca, Entheogens, N,N-Dimethyltryptamine, Psychedelic drug, DMT

LONDON, United Kingdom, July 30, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT”) therapies, has today published its first quarter results for the three months ended May 31, 2021. A full copy of the results can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise indicated, all currency references are to Canadian dollars.

Key Points: 
  • LONDON, United Kingdom, July 30, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (the Company or Small Pharma), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (DMT) therapies, has today published its first quarter results for the three months ended May 31, 2021.
  • In March 2021, Small Pharma successfully raised $58 million from new and existing securityholders, leading to the completion of the Reverse Takeover and listing on the TSXV in May 2021.
  • In July 2021, Small Pharma launched its DMT-assisted therapy training program to educate therapists on the process required to support treatment delivery of Small Pharmas DMT-assisted therapy clinical trials.
  • In July 2021, Small Pharma received granted status under patent number GB2585978 for its UK patent application GB2008303.6.

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

Retrieved on: 
Vendredi, juillet 30, 2021
Organic compounds, Epidermal growth factor receptor, Oncogenes, KRAS, Chemical compounds, Quinazolines, Cancer, Amines, Chloroarenes, Gefitinib, Icotinib

Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.

Key Points: 
  • Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.
  • The published data supported the Investigational New Drug application for the ongoing AFM24 Phase 1/2a dose escalation study.
  • The published data were the basis for the Investigational New Drug (IND) clearance for Affimeds ongoing Phase 1/2a study with AFM24 monotherapy in patients with EGFR expressing solid tumors.
  • AFM24 is effective against many EGFR-positivetumorcells, regardless of EGFR expression level and KRAS/BRAF mutational status within in vitro studies.

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

Retrieved on: 
Mercredi, juillet 28, 2021
Entheogens, Health sciences, Amines, Health, Ayahuasca, Clinical research, N,N-Dimethyltryptamine, Drug discovery, Design of experiments, Clinical trial, MindMed

The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients.

Key Points: 
  • The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients.
  • The Phase 1 clinical trial has received all necessary regulatory approvals in Switzerland and subject enrollment has been initiated.
  • MindMed plans to study an intravenous administration method [during its Phase 1 clinical trial] that would induce a stable and prolonged DMT experience.
  • Forward-looking information in this news release include, but are not limited to, statements regarding the start of MindMed's Phase 1 clinical trial of DMT, the successful outcome of the Phase 1 clinical trial, the ability to initiate a Phase 2 clinical trial of DMT, regulatory approvals, the effects of DMT, subject enrollment and the administration method of DMT.

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Retrieved on: 
Mardi, juillet 27, 2021
Psychoactive drugs, Amines, Entheogens, Ayahuasca, N,N-Dimethyltryptamine, Hallucinations, Psychedelic drug

Toronto, Ontario--(Newsfile Corp. - July 27, 2021) - Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Algernon Pharmaceuticals Inc.  (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19, and Pharmadrug, a Biotech Company Focused on the R&D of Natural Based Medicines are pleased to announce the DMT Conference.

Key Points: 
  • The two-day virtual conference is to take place on September 9-10th 2021, starting at 12 pm EDT.
  • Join us as we take a scientific deep dive into the dynamic field of DMT therapeutics, with expert panels and engaging discussions.
  • Our Molecular Masterclasses are a speaker series designed for deep dives into the world's favourite psychoactive and psychedelic substances.
  • Each event will explore one drug, and feature a curated group of industry experts and thought leaders from around the world.

Core One Labs’ Akome Seeks to Revolutionize Treatment of Parkinson’s Disease and Submits Application to Protect IP

Retrieved on: 
Lundi, juillet 26, 2021
Amines, Psychoactive drugs, Entheogens, Hallucinations, Psychedelic drug, N,N-Dimethyltryptamine, DMT, Parkinson

Akomes AKO004 psychedelic drug formulation, for use in the treatment of Parkinsons disease, is a composition comprising the psychedelic compound N,N-dimethyltryptamine (DMT) and, a specifically chosen, naturally occurring plant bioactive.

Key Points: 
  • Akomes AKO004 psychedelic drug formulation, for use in the treatment of Parkinsons disease, is a composition comprising the psychedelic compound N,N-dimethyltryptamine (DMT) and, a specifically chosen, naturally occurring plant bioactive.
  • 1It is estimated that over 10 million people worldwide are living with Parkinsons disease.
  • Within the United States it is further estimated that over 930,000 people live with Parkinsons disease and approximately 60,000 more are diagnosed each year.
  • Akomes AKO0004 drug formulation presents strong indication as a viable candidate for the treatment of Parkinsons disease, stated Joel Shacker CEO of the Company.

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

Retrieved on: 
Mardi, juillet 20, 2021
Organic compounds, Chemical compounds, Quinazolines, Tyrosine kinase receptors, Amines, Astellas Pharma, Erlotinib, Ethers, Epidermal growth factor receptor, Chemistry

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.

Key Points: 
  • NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.
  • Both product candidates are exclusively licensed forU.S.commercialization withGalderma Holding SA.
  • The Companys pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment ofpalmoplantar keratoderma, and preclinical assets tapinarof and roflumilast.
  • For additional information, please visit www.sol-gel.com .

ANGUS Chemical Company Launches New Alkalizer For Hair Colorant Systems

Retrieved on: 
Jeudi, juillet 15, 2021
Chemistry, Physical sciences, Chemical substances, Amines, Ethanolamine, Ethanolamines, Ammonia, International Nomenclature of Cosmetic Ingredients, 2AP, MEA

BUFFALO GROVE, Ill., July 15, 2021 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the commercial introduction of DL-2AP ULTRA PC (INCI: Aminopropanol), a new alkalizer for hair colorant systems.

Key Points: 
  • BUFFALO GROVE, Ill., July 15, 2021 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the commercial introduction of DL-2AP ULTRA PC (INCI: Aminopropanol), a new alkalizer for hair colorant systems.
  • DL-2AP ULTRA PC is the latest addition to ANGUS' portfolio of high-purity ULTRA PC-grade multifunctional amino alcohols for personal care and cosmetics.
  • ANGUS is launching DL-2AP ULTRA PC in response to the fast-growing market demand for alternatives to commonly used alkalizing agents, such as monoethanolamine (MEA) and ammonia.
  • "In laboratory evaluations, permanent hair colorant systems formulated with DL-2AP ULTRA PC showed excellent lifting performance, as well as color deposition and fastness comparable to ammonia and MEA," said Mrunalini Dhamdhere, Global Technical Manager, ANGUS Home and Personal Care.

Global Hexamethyldisilazane (HMDS) Market (Value, Volume) Analysis & Forecasts, 2016-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Lundi, juillet 5, 2021
Chemicals, Plastics, Manufacturing, Chemistry, Physical sciences, Trimethylsilyl compounds, Natural sciences, Amines, Bis(trimethylsilyl)amine, Market segmentation, Silazane, Market

Globally, the Hexamethyldisilazane market is mainly driven by growing demand for semiconductor processing and pharmaceutical intermediate.

Key Points: 
  • Globally, the Hexamethyldisilazane market is mainly driven by growing demand for semiconductor processing and pharmaceutical intermediate.
  • The report presents the analysis of Hexamethyldisilazane Market for the historical period of 2016-2020 and the forecast period of 2021-2026.
  • 5 Global Hexamethyldisilazane Market Segmentation By Application (By Value, By Volume)
    5 1 Competitive Scenario of Global Hexamethyldisilazane Market: By Application
    6 Global Hexamethyldisilazane Market Segmentation By Type (By Value.
  • By Volume)
    6 1 Competitive Scenario of Global Hexamethyldisilazane Market: By Type
    7 1 Competitive Scenario of Global Hexamethyldisilazane Market: By Region
    8 North America Hexamethyldisilazane Market (By Value, By Volume): An Analysis (2016-2026)
    9 Europe Hexamethyldisilazane Market (By Value, By Volume): An Analysis (2016-2026)
    10 Asia Pacific Hexamethyldisilazane Market (By Value, By Volume): An Analysis (2016-2026)
    12 1 1 Market Attractiveness Chart of Global Hexamethyldisilazane Market - By Application, By Volume (Year-2026)
    12 1 2 Market Attractiveness Chart of Global Hexamethyldisilazane Market - By Type, By Volume (Year-2026)
    12 1 3 Market Attractiveness Chart of Global Hexamethyldisilazane Market - By Region, By Volume (Year-2026)
    14 Company Profiles (Business Description, Financial Analysis, Business Strategy)

Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Retrieved on: 
Jeudi, juillet 1, 2021
Health sciences, Pharmacology, Amines, Dosage forms, Ayahuasca, Entheogens, N,N-Dimethyltryptamine, Psychedelic drug, Transdermal patch, Investigational New Drug

Psilera has developed a patent-pending DMT transdermal patch to be assessed in a Phase 1b clinical trial with an investigational new drug (IND) filing anticipated in H2 2021.

Key Points: 
  • Psilera has developed a patent-pending DMT transdermal patch to be assessed in a Phase 1b clinical trial with an investigational new drug (IND) filing anticipated in H2 2021.
  • Transdermal administration can deliver drugs directly into the bloodstream and reduce DMT metabolism while providing steady, low-dose therapies.
  • This will be a major catalyst for Psilera to efficiently optimize its drug pipeline into lead candidates for clinical development.
  • About Psilera Bioscience - Psilera Inc. is a psychedelic-based biotechnology company developing its proprietary neuromodulator pipeline to target central nervous system disorders.